Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania

[1]  F. Moshi,et al.  Determinants for choice of home birth over health facility birth among women of reproductive age in Tanzania: an analysis of data from the 2015-16 Tanzania demographic and health survey and malaria indicator survey , 2020, BMC Pregnancy and Childbirth.

[2]  P. Ringwald,et al.  Prevalence of molecular markers of artemisinin and lumefantrine resistance among patients with uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2015 , 2018, Malaria Journal.

[3]  Q. Bassat,et al.  Drug-Resistant Polymorphisms and Copy Numbers in Plasmodium falciparum, Mozambique, 2015 , 2018, Emerging infectious diseases.

[4]  A. Ghansah,et al.  Efficacy of Artesunate/Amodiaquine in the Treatment of Uncomplicated Malaria among Children in Ghana. , 2017, The American journal of tropical medicine and hygiene.

[5]  B. Pradines,et al.  Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal. , 2017, International journal of antimicrobial agents.

[6]  D. Fidock,et al.  A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study , 2017, The Lancet. Infectious diseases.

[7]  D. Kwiatkowski,et al.  Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. , 2017, The Lancet. Infectious diseases.

[8]  T. Horii,et al.  Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda , 2017, Malaria Journal.

[9]  P. Awono-ambene,et al.  Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates , 2016, Malaria Journal.

[10]  P. Kofoed,et al.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau – An Open-Label Non-Inferiority Randomised Clinical Trial , 2016, PloS one.

[11]  T. Bousema,et al.  In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo , 2016, Malaria Journal.

[12]  C. Rogier,et al.  A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. , 2016, The New England journal of medicine.

[13]  Adugna Woyessa,et al.  Therapeutic Efficacy of Artemether-Lumefantrine (Coartem®) in Treating Uncomplicated P. falciparum Malaria in Metehara, Eastern Ethiopia: Regulatory Clinical Study , 2016, PloS one.

[14]  D. Mathanga,et al.  In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014 , 2016, Malaria Journal.

[15]  S. Abdulla,et al.  Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries , 2016, Malaria Journal.

[16]  F. Mwanza.  Health risks associated with urban farming: Cryptosporidium and non-sorbitol fermenting Escherichia coli as indicator organisms in Dar Es Salaam, Tanzania , 2016 .

[17]  O. Gaye,et al.  [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine]. , 2016, Medecine et sante tropicales.

[18]  Key Messages.  Artemisinin and artemisinin-based combination therapy resistance , 2016 .

[19]  F. Ntoumi,et al.  Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study , 2015, Malaria Journal.

[20]  Saorin Kim,et al.  Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment , 2015, Antimicrobial Agents and Chemotherapy.

[21]  G. Malenga,et al.  Monitoring the efficacy of artemether-lumefantrine for the treatment of uncomplicated malaria in Malawian children , 2015, Malaria Journal.

[22]  J. Buza,et al.  Monitoring of efficacy and safety of artemisinin-based anti-malarials for treatment of uncomplicated malaria: a review of evidence of implementation of anti-malarial therapeutic efficacy trials in Tanzania , 2015, Malaria Journal.

[23]  M. Kamya,et al.  Efficacy and Safety of Fixed-Dose Artesunate-Amodiaquine vs. Artemether-Lumefantrine for Repeated Treatment of Uncomplicated Malaria in Ugandan Children , 2014, PloS one.

[24]  B. Hamainza,et al.  Therapeutic efficacy of artemether-lumefantrine on treatment of uncomplicated Plasmodium falciparum mono-infection in an area of high malaria transmission in Zambia , 2014, Malaria Journal.

[25]  N. Lucchi,et al.  Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-1 Piperaquine for the Treatment of Uncomplicated Malaria in Children 2 in Zaire and Uíge Provinces , Angola 3 4 , 2014 .

[26]  P. Rosenthal,et al.  Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[28]  L. Otieno,et al.  Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study , 2014, Malaria Journal.

[29]  Koen Peeters Grietens,et al.  An innovative tool for moving malaria PCR detection of parasite reservoir into the field , 2013, Malaria Journal.

[30]  S. P. Kachur,et al.  A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in western Kenya , 2013, Malaria Journal.

[31]  M. Petzold,et al.  Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania , 2013, Malaria Journal.

[32]  T. Theander,et al.  Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. , 2011, The American journal of tropical medicine and hygiene.

[33]  C. Happi,et al.  Feasibility, acceptability and use of artemisinin-based combination therapy , 2010 .

[34]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[35]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[36]  Organización Mundial de la Salud.  Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations , 2008 .

[37]  G. Saunders.  The treatment of malaria. , 1947, Missouri medicine.

[38]  T. Horder.  Health and Social Welfare , 1941, Nature.